KALY Confirms Pharmaceutical Cannabis Extract Report On Recent Trials Scheduled For Today

KALY is utilizing its patented cannabis extraction process to develop numerous wellness products both internally and through partnerships.

DALLAS, March 21, 2019 (GLOBE NEWSWIRE) — — via OTC PR WIRE

Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed the company plans to publish its phase one research on the pilot treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates.

The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies.

In addition to developing pharmaceutical products internally and through partnerships, KALY is utilizing its patented cannabis extraction process to develop numerous wellness products both internally and through partnerships.